Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

13. November 2025 05:00 ET | Quelle: 4TEEN4 Pharmaceuticals GmbH

4TEEN4 Extends Series C Financing Round to €55 Million, Supporting Expanded Clinical Development of Procizumab in Cardiogenic Shock

4TEEN4 extends series C financing to EUR 55M ($64M) to increase footprint of the Phase 2a study across Europe and to support planned expansion into US.
23. Juli 2025 05:50 ET | Quelle: 4TEEN4 Pharmaceuticals GmbH

4TEEN4 Doses First Patient in Phase 1b/2a Trial of Procizumab, a Monoclonal Antibody Targeting the Biological Driver of Shock

The trial will evaluate safety, dosing, and efficacy in patients with cardiogenic shock Hennigsdorf/ Berlin, July 23, 2025 – 4TEEN4 Pharmaceuticals GmbH today announced that the first patient has...
15. Juli 2025 05:00 ET | Quelle: 4TEEN4 Pharmaceuticals GmbH

4TEEN4 Announces Publication in European Journal of Heart Failure Demonstrating First-in-Human Shock Reversal Evidence for Procizumab in Three Compassionate Use Cases

Data from three terminally ill cardiogenic shock patients showcase potential of procizumab to safely reverse shock within 48 hours and provide promising first-in-human evidence on the translatability...